Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR3006A + BR3006B + BR3006C
- Development stage
- Phase 4
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR3006A + BR3006B + BR3006C is a fixed-dose combination of three small molecule antidiabetic agents: dapagliflozin 10 mg (a sodium-glucose cotransporter 2 inhibitor), pioglitazone 30 mg (a thiazolidinedione), and metformin hydrochloride 1000 mg (a biguanide). Developed by Boryung Pharmaceutical, this combination is being studied for the treatment of type 2 diabetes mellitus. Its mechanism of action involves complementary glycemic control through SGLT2 inhibition (promoting urinary glucose excretion), PPARγ activation (improving insulin sensitivity), and decreased hepatic glucose production/increased peripheral uptake. Clinical evaluation to date is focused on pharmacokinetics and safety in healthy adult volunteers under both fasting and fed conditions. The formulation aims to simplify multidrug therapy for type 2 diabetes by combining these established agents into a single oral tablet[2][7][8].
- Other names
- dapagliflozin + pioglitazone + metformin
02
Targets
ND1 (Mitochondrial electron transport chain complex I)PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on BR3006A + BR3006B + BR3006C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR3006A + BR3006B + BR3006C.